MedVellum
MedVellum
Back to Library
Obstetrics
Hepatology
Maternal Medicine

Obstetric Cholestasis

High EvidenceUpdated: 2025-12-22

On This Page

Red Flags

  • Stillbirth risk (increases with bile acids >100)
  • Severe pruritus
  • Markedly elevated bile acids
Overview

Obstetric Cholestasis

1. Clinical Overview

Summary

Obstetric cholestasis (intrahepatic cholestasis of pregnancy, ICP) is a pregnancy-specific liver disorder characterised by intense pruritus (itching) and elevated serum bile acids. It typically presents in the third trimester and resolves rapidly after delivery. The main concern is the risk of stillbirth, which is unpredictable and increases when bile acids are >40 μmol/L, with highest risk at >100 μmol/L. Treatment involves ursodeoxycholic acid (UDCA) to reduce bile acids and relieve itching, and planned delivery at 37-38 weeks (earlier if severe) to reduce stillbirth risk.

Key Facts

  • Symptoms: Intense pruritus (palms and soles, worse at night) without primary rash
  • Biochemistry: Raised bile acids (>10 μmol/L), raised ALT
  • Key Risk: Stillbirth (sudden, unpredictable; higher if bile acids >100)
  • Treatment: Ursodeoxycholic acid (UDCA)
  • Delivery: Planned at 37-38 weeks (earlier if severe)
  • Prognosis: Resolves after delivery; may recur in future pregnancies

Clinical Pearls

"Itch Without Rash": The pruritus in ICP has no primary rash. Excoriations and scratch marks are secondary. Always check bile acids.

"Palms and Soles, Worse at Night": The classic distribution. Patients often describe unbearable itching that disrupts sleep.

"Bile Acids >100 = High Risk": Stillbirth risk increases significantly with bile acids >100 μmol/L. Consider earlier delivery.

"Resolves Post-Delivery": Symptoms and biochemistry resolve within days to weeks of delivery. If persistent, investigate other causes.


2. Epidemiology

Incidence

  • 0.5-1.5% of pregnancies in UK
  • Higher in South Asian and South American populations

Risk Factors

FactorNotes
Previous ICP45-70% recurrence
Family historyGenetic predisposition
Multiple pregnancyHigher incidence
IVF pregnancyPossibly higher risk
Hepatitis CAssociated

3. Pathophysiology

Mechanism

  • Impaired bile acid transport in hepatocytes
  • Exacerbated by high oestrogen levels in pregnancy
  • Genetic variants in bile salt transporters (ABCB4, ABCB11)

Why Stillbirth?

  • High bile acids cross placenta
  • Cause fetal cardiac arrhythmias
  • Vasoconstriction of placental vessels
  • Usually sudden and unpredictable

4. Clinical Presentation

Symptoms

FeatureDescription
PruritusIntense, generalised; worst on palms and soles
TimingWorse at night; disrupts sleep
RashNo primary rash; excoriations from scratching
OnsetUsually 3rd trimester (can be earlier)
OtherDark urine, pale stools, mild jaundice (rare)

Symptoms Resolve


Symptoms typically peak before delivery
Common presentation.
Rapid resolution within 48 hours to 2 weeks post-delivery
Common presentation.
5. Clinical Examination

General

  • Excoriations and scratch marks (secondary)
  • No primary rash
  • Rarely: Mild jaundice

Abdominal

  • Uterus size appropriate for dates
  • Normal fetal movements initially

6. Investigations

First-Line

TestFinding
Serum bile acidsElevated (>0 μmol/L diagnostic)
LFTsRaised ALT (often 2-10x normal); may precede bile acid rise
BilirubinUsually normal or mildly elevated

Risk Stratification by Bile Acids

Bile AcidsRisk Category
10-39 μmol/LMild
40-99 μmol/LModerate
≥100 μmol/LSevere (highest stillbirth risk)

Exclude Other Causes

  • Hepatitis serology (A, B, C, E)
  • Liver ultrasound (for biliary obstruction)
  • Autoimmune screen if needed

7. Management

Management Approach

┌──────────────────────────────────────────────────────────┐
│   OBSTETRIC CHOLESTASIS MANAGEMENT                       │
├──────────────────────────────────────────────────────────┤
│                                                          │
│  SYMPTOMATIC RELIEF:                                      │
│  • Emollients (aqueous cream, menthol cream)             │
│  • Chlorphenamine (antihistamine - temporary relief)     │
│  • Cool baths                                            │
│                                                          │
│  URSODEOXYCHOLIC ACID (UDCA):                             │
│  • 10-15 mg/kg/day in 2 divided doses                    │
│  • Reduces bile acids and pruritus                       │
│  • Evidence for fetal benefit uncertain (PITCHES trial)  │
│                                                          │
│  MONITORING:                                              │
│  • Weekly bile acids and LFTs                            │
│  • Fetal movements (advise woman to report changes)      │
│  • CTG (limited predictive value for stillbirth)         │
│                                                          │
│  DELIVERY TIMING:                                         │
│  • Bile acids <40: 38-39 weeks                           │
│  • Bile acids 40-99: 37-38 weeks                         │
│  • Bile acids ≥100: Consider earlier (from 36 weeks)     │
│  • Balance stillbirth risk vs prematurity                │
│                                                          │
│  VITAMIN K:                                               │
│  • Consider oral vitamin K if prolonged cholestasis      │
│    (impaired fat-soluble vitamin absorption)             │
│                                                          │
│  POSTNATAL:                                               │
│  • Symptoms resolve within days to weeks                 │
│  • Repeat LFTs at 6-8 weeks to confirm resolution        │
│  • Counsel about recurrence (45-70%)                     │
│  • Avoid oestrogen-containing contraception              │
│                                                          │
└──────────────────────────────────────────────────────────┘

8. Complications

Fetal

  • Stillbirth (main concern; sudden and unpredictable)
  • Preterm birth (spontaneous or iatrogenic)
  • Meconium-stained liquor
  • Fetal distress

Maternal

  • Severe pruritus (psychological impact)
  • Vitamin K deficiency (rare)
  • PPH (if vitamin K deficiency)

9. Prognosis & Outcomes

Stillbirth Risk

Bile AcidsApproximate Risk
<40 μmol/L~0.1% (background)
40-99 μmol/L~1%
≥100 μmol/L~3-5%

After Pregnancy

  • Rapid resolution of symptoms and biochemistry
  • May recur in future pregnancies (45-70%)
  • May recur with COC use

10. Evidence & Guidelines

Key Guidelines

  1. RCOG Green-top Guideline No. 43: Obstetric Cholestasis
  2. UpToDate: Intrahepatic Cholestasis of Pregnancy

Key Evidence

PITCHES Trial (2019)

  • UDCA did not significantly improve perinatal outcomes
  • But may still help symptom relief

Stillbirth Risk

  • Meta-analyses confirm risk increases with bile acid level

11. Patient/Layperson Explanation

What is Obstetric Cholestasis?

Obstetric cholestasis (ICP) is a liver condition that happens in pregnancy. It causes intense itching, especially on the palms and soles, and is diagnosed by a blood test showing raised bile acids.

Why Does it Matter?

The main concern is a slightly increased risk of stillbirth. This risk is higher when bile acid levels are very high. That's why your doctors will monitor you closely and may recommend having your baby a bit earlier than your due date.

What Are the Symptoms?

  • Severe itching (especially palms and soles, worse at night)
  • No rash (just scratch marks)
  • Sometimes dark urine or pale stools

How is it Treated?

  • Creams to soothe itching
  • Ursodeoxycholic acid (UDCA) tablets to lower bile acids
  • Earlier delivery (usually around 37-38 weeks) to reduce the stillbirth risk
  • Monitoring with regular blood tests

What Happens After Birth?

The itching and abnormal blood tests go away within a few weeks of delivery. If you get pregnant again, there's a chance (about 50-70%) it could happen again.


12. References

Primary Guidelines

  1. Royal College of Obstetricians and Gynaecologists. Green-top Guideline No. 43: Obstetric Cholestasis. 2011. rcog.org.uk

Key Studies

  1. Chappell LC, et al. Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial. Lancet. 2019;394(10201):849-860. PMID: 31378395

Last updated: 2025-12-22

At a Glance

EvidenceHigh
Last Updated2025-12-22

Red Flags

  • Stillbirth risk (increases with bile acids &gt;100)
  • Severe pruritus
  • Markedly elevated bile acids

Clinical Pearls

  • **"Itch Without Rash"**: The pruritus in ICP has no primary rash. Excoriations and scratch marks are secondary. Always check bile acids.
  • **"Palms and Soles, Worse at Night"**: The classic distribution. Patients often describe unbearable itching that disrupts sleep.
  • **"Bile Acids &gt;100 = High Risk"**: Stillbirth risk increases significantly with bile acids &gt;100 μmol/L. Consider earlier delivery.
  • **"Resolves Post-Delivery"**: Symptoms and biochemistry resolve within days to weeks of delivery. If persistent, investigate other causes.

Guidelines

  • NICE Guidelines
  • BTS Guidelines
  • RCUK Guidelines